These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 10792085)

  • 1. Correlation of prostate-specific antigen before prostate cancer detection and clinicopathologic features: evaluation of mass screening populations.
    Ito K; Kubota Y; Suzuki K; Shimizu N; Fukabori Y; Kurokawa K; Imai K; Yamanaka H
    Urology; 2000 May; 55(5):705-9. PubMed ID: 10792085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of prostate-specific antigen velocity in screening for prostate cancer.
    Ito K; Yamamoto T; Ohi M; Kubota Y; Fukabori Y; Kurokawa K; Suzuki K; Yamanaka H
    Int J Urol; 2002 Jun; 9(6):316-21. PubMed ID: 12110095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
    Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W
    Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does PSA velocity predict prostate cancer in pre-screened populations?
    Schröder FH; Roobol MJ; van der Kwast TH; Kranse R; Bangma CH
    Eur Urol; 2006 Mar; 49(3):460-5; discussion 465. PubMed ID: 16442212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis.
    Martin NE; Chen MH; Catalona WJ; Loeb S; Roehl KA; D'Amico AV
    Cancer; 2008 Aug; 113(4):717-22. PubMed ID: 18615505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
    Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
    Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH.
    King CR; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
    Urology; 2007 Apr; 69(4):732-7. PubMed ID: 17445660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
    Vickers AJ; Wolters T; Savage CJ; Cronin AM; O'Brien MF; Pettersson K; Roobol MJ; Aus G; Scardino PT; Hugosson J; Schröder FH; Lilja H
    Eur Urol; 2009 Nov; 56(5):753-60. PubMed ID: 19682790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less.
    Yamamoto T; Ito K; Ohi M; Kubota Y; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
    Urology; 2001 Dec; 58(6):994-8. PubMed ID: 11744475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
    Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
    Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of prostate specific antigen for early stage prostate cancer detection.
    Imai K; Ichinose Y; Kubota Y; Yamanaka H; Sato J; Saitoh M; Watanabe H; Ohe H
    Jpn J Clin Oncol; 1994 Jun; 24(3):160-5. PubMed ID: 7516445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program.
    Eggener SE; Yossepowitch O; Roehl KA; Loeb S; Yu X; Catalona WJ
    Urology; 2008 Jun; 71(6):1016-9. PubMed ID: 18358515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.
    Berger AP; Deibl M; Strasak A; Bektic J; Pelzer A; Steiner H; Spranger R; Fritsche G; Bartsch G; Horninger W
    Urology; 2006 Nov; 68(5):1067-71. PubMed ID: 17095070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations.
    Eastham JA; Riedel E; Scardino PT; Shike M; Fleisher M; Schatzkin A; Lanza E; Latkany L; Begg CB;
    JAMA; 2003 May; 289(20):2695-700. PubMed ID: 12771116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands.
    Jyoti SK; Blacke C; Patil P; Amblihalli VP; Nicholson A
    Cancer Causes Control; 2018 Jan; 29(1):87-92. PubMed ID: 28918559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple Risk Stratification to Detect Prostate Cancer with High Gleason Score in Repeat Biopsies in a Population Screening Follow-up Study.
    Kitagawa Y; Urata S; Mizokami A; Nakashima K; Koshida K; Nakashima T; Miyazaki K; Namiki M
    Anticancer Res; 2015 Sep; 35(9):5031-6. PubMed ID: 26254404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL.
    Ito K; Yamamoto T; Ohi M; Kurokawa K; Suzuki K; Yamanaka H
    Urology; 2003 Apr; 61(4):760-4. PubMed ID: 12670561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality.
    Nguyen PL; Chen MH; Renshaw AA; Sussman B; D'Amico AV
    Urology; 2007 Aug; 70(2):288-93. PubMed ID: 17826491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.